Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Charlottesville, Virginia Clinical Trials

A listing of Charlottesville, Virginia clinical trials actively recruiting patient volunteers.

RESULTS

Found (33) clinical trials

Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer

Approximately 30 subjects across approximately 5 United States (US) sites will be enrolled in the Phase 1 portion of the study and approximately 69-84 subjects across approximately 15 US sites will be enrolled in the Phase 2A portion of the study. The Phase 1 portion of the study will follow ...

Phase

5.55 miles

Learn More »

Study Evaluating KTE-C19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

The primary objectives of this study are to evaluate the safety and efficacy of KTE-C19 in pediatric and adolescent participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL).

Phase

5.55 miles

Learn More »

A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced Measurable Biopsy-accessible Cancers

This is an open-label, multicenter Phase 1/2 study of the CTLA-4 antibody, tremelimumab, and the PD-L1 antibody, durvalumab (MEDI4736), in combination with the tumor microenvironment (TME) modulator polyICLC, a TLR3 agonist, in subjects with advanced, measurable, biopsy-accessible cancers.

Phase

5.55 miles

Learn More »

Her2-BATS and Pembrolizumab in Metastatic Breast Cancer

Once subjects are determined eligible, white blood cells (lymphocytes) are collected via leukapheresis procedure. Depending on arm/schedule, about 4-5 weeks later, study treatment will begin. For HER2 BATs, the white blood cells, specifically T cells, are then mixed with two proteins - OKT3 and IL-2 -- which activates the cells ...

Phase

5.55 miles

Learn More »

Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC

OUTLINE: This is a multi-center study. INVESTIGATIONAL TREATMENT: Phase I, Cohort 1 Induction Therapy: Carboplatin AUC 6 IV, Day 1 Nab-paclitaxel 100 mg/m^2 IV, Days 1, 8, 15 pembrolizumab 2 mg/kg IV, Day 1 Cycle length: 21 days; number of cycles: 4 Phase I, Cohort 1 Maintenance Therapy: For subjects ...

Phase

5.55 miles

Learn More »

Determine the Safety/Efficacy of Ticagrelor for Maintaining Patency of Arterio-Venous Fistulae Created for Hemodialysis

This study is a randomized, placebo-controlled, single blind clinical trial. Seventy patients with ESRD on chronic HD and a functioning AVF will be recruited. Consent form will be obtained. History and physical, dialysis parameters and laboratory data (CBC, CMP, PTT & INR) will be obtained throughout the study. The following ...

Phase

5.55 miles

Learn More »

Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer

This study will evaluate the safety and disease control rate of the combination of pembrolizumab plus low-dose interleukin-2 in patients who have either advanced melanoma or renal cell cancer.

Phase

5.55 miles

Learn More »

A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma

This study evaluates whether it is safe to administer a peptide vaccine with ipilimumab. This study will also evaluate the effects of the combination of the peptide vaccine and ipilimumab on the immune system. The investigators will monitor these effects by performing tests in the laboratory on participants' blood, a ...

Phase

5.55 miles

Learn More »

Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian Primary Peritoneal or Fallopian Tube Cancer

PRIMARY OBJECTIVES: I. Assess safety and tolerability of the combination therapy carboplatin, gemcitabine (gemcitabine hydrochloride) and M6620 (VX-970) (rad3-related [ATR] kinase inhibitor VX-970) in adult women with platinum sensitive recurrent high grade serous or high grade endometrioid ovarian, primary peritoneal or fallopian tube cancer. (Phase I Dose Escalation/Safety Lead-in) II. ...

Phase

5.55 miles

Learn More »

A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib

This study evaluates whether it is safe to administer a helper peptide vaccine with dabrafenib and trametinib. This study will also evaluate the effects of the combination of the peptide vaccine and dabrafenib and trametinib on the immune system. We will monitor these effects by performing tests in the laboratory ...

Phase

5.55 miles

Learn More »